BBI News and Press, Brickell Biotech Inc.

Clinical-stage biotech Brickell Biotech, Inc. ( NASDAQ: BBI ) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc. Accordingly, the company said that BBI’s name, logo, website, and branding would chan...

New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...

Brickell Biotech, Inc. (BBI) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief Financial Off...

Brickell Biotech press release ( NASDAQ: BBI ): Q2 GAAP EPS of -$0.01 beats by $1.43 . Revenue of $4.32M (+2780.0% Y/Y) beats by $1.18M . The Company expects its cash and cash equivalents as of June 30, 2022, combined with $2.0 million from expected n...

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...

Short squeeze penny stocks are the unicorns of the stock market today. They aren’t always in play, but when they are, they can wake up the entire small- and micro-cap stock arena. That’s what has happened over the last few weeks and more actively in the previous few days. ...

Brickell Biotech ( NASDAQ: BBI ) was notified by Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. The stock will continue to be listed and traded on the exchange. Shares trading 1.4% higher premarket. ...

BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmun...

BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics...